

## Supporting Information

Table S1 Interpretive results of MIC Breakpoints (mg/L) for *Staphylococcus* spp.

Strain	MRSA ATCC® 6538	MSSA ATCC® 29213	MRSA FMV 1504A/08	MSSA FMV 77/2015	MRSP FMV 4877/10	MRSA SM39	MRSA SM52	MRSE FMV 60/2012	MRSS FMV 57/2013B	MRSP GV 818/2017	MRSP FMV 56/2013A	MRSP FMV 57/2013A
Antimicrobial												
Interpretive results of MIC Breakpoints (mg/L) <sup>a</sup>												
AK	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	>32 (R)	32 (I)	≤8 (S)	16 (S)	≤8 (S)	16 (S)	≤8 (S)
AMP	≤ 0.25 (R)	> 8 (R)	> 8 (R)	≤ 0.25 (R)	> 8 (R)	> 8 (R)	> 8 (R)	> 8 (R)	> 8 (R)	4 (R)	> 8 (R)	> 8 (R)
AMC	> 8/4 (R)	≤ 4/2 (S)	> 8/4 (R)	≤ 4/2 (S)	> 8/4 (R)	> 8/4 (R)	> 8/4 (R)	> 8/4 (R)	> 8/4 (R)	> 8/4 (R)	> 8/4 (R)	> 8/4 (R)
C	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	≤8 (S)	16 (R)
CD	≤ 0.25 (S)	≤ 0.25 (S)	1 (I)	≤ 0.25 (S)	>2 (R)	>2 (R)	1 (I)	>2 (R)	≤ 0.25 (S)	≤ 0.5 (S)	>2 (R)	>2 (R)
FOX	> 4 (R)	≤4 (S)	> 4 (R)	≤4 (S)	> 4 (R)	> 4 (R)	> 4 (R)	> 4 (R)	> 4 (R)	≤4 (S)	≤4 (S)	≤4 (S)
CP	≤1 (S)	≤1 (S)	>2 (R)	≤1 (S)	>2 (R)	>2 (R)	>2 (R)	>2 (R)	≤1 (S)	≤1 (S)	>2 (R)	>2 (R)
CPT	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	1 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)
DAP	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)
E	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	> 4 (R)	> 4 (R)	≤ 0.5 (S)	> 4 (R)	≤ 0.5 (S)	≤ 0.5 (S)	> 4 (R)	> 4 (R)
FA	≤2 (S)	≤2 (S)	≤2 (S)	≤2 (S)	≤2 (S)	≤2 (S)	≤2 (S)	>2 (R)	>2 (R)	≤2 (S)	≤2 (S)	≤2 (S)
FOS	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)
F	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	64 (I)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)	≤32 (S)
CN	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	> 8 (R)	4 (S)	2 (S)	> 8 (R)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)
IMP	≤4 (S)	≤4 (S)	≤4 (S)	≤4 (S)	8 (I)	≤4 (S)	≤4 (S)	>8 (I)	≤4 (S)	≤4 (S)	≤4 (S)	≤4 (S)
LVX	≤1 (S)	≤1 (S)	>4 (S)	≤1 (S)	>4 (S)	4 (S)	>4 (S)	>4 (S)	≤1 (S)	≤1 (S)	>4 (S)	>4 (S)
LZD	4 (S)	4 (S)	4 (S)	2 (S)	4 (S)	2 (S)	2 (S)	4 (S)	4 (S)	4 (S)	2 (S)	2 (S)
MIN	≤1 (S)	≤1 (S)	≤1 (S)	8 (I)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	8 (I)	> 8 (R)
MXF	≤ 0.5 (S)	≤ 0.5 (S)	>1 (R)	≤ 0.5 (S)	>1 (R)	≤ 0.5 (S)	>1 (R)	>1 (R)	>1 (R)	≤ 0.5 (S)	>1 (R)	>1 (R)
MUP	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)	<256 (S)
NXN	≤4 (S)	≤4 (S)	>8 (R)	≤4 (S)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	8 (I)	>8 (R)	>8 (R)
OX	≤ 0.25 (S)	≤ 0.25 (S)	>2 (R)	≤ 0.25 (S)	>2 (R)	>2 (R)	>2 (R)	>2 (R)	>2 (R)	>2 (R)	>2 (R)	>2 (R)
P	≤0.12 (R)	≤0.12 (S)	>8 (R)	≤0.12 (S)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	>8 (R)
PRS	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)
RIF	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)	≤ 0.5 (S)
SYN	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)
TEI	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	8 (I)	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)
TE	≤1 (S)	≤1 (S)	≤1 (S)	>8 (R)	>8 (R)	≤1 (S)	≤1 (S)	>8 (R)	>8 (R)	≤1 (S)	>8 (R)	>8 (R)
TO	≤1 (S)	≤1 (S)	≤1 (S)	≤1 (S)	>8 (R)	>8 (R)	>8 (R)	>8 (R)	≤1 (S)	≤1 (S)	≤1 (S)	>8 (R)
SXT	≤ 2/38 (S)	≤ 2/38 (S)	≤ 2/38 (S)	≤ 2/38 (S)	>4/76 (R)	≤ 2/38 (S)	≤ 2/38 (S)	≤ 2/38 (S)	>4/76 (R)	>4/76 (R)	≤ 2/38 (S)	≤ 2/38 (S)
VA	1 (S)	1 (S)	1 (S)	1 (S)	1 (S)	2 (S)	2 (S)	4 (S)	1 (S)	1 (S)	1 (S)	2 (S)

a - Susceptibility was accessed according to Clinical and Laboratory Standards Institute (CLSI) guidelines M100-S27.

**Abbreviations** AK Amikacin, AMP Ampicillin, AMC Amoxicillin/Clavulanic Acid, C Cloranfenicol (Chloramphenicol), Cd Clindamycin, FOX Cefoxitin, CIP Ciprofloxacin, CPT Ceftaroline, DAP Daptomycin, E Erythromycin, FA Fusidic acid, FOS Fosfomycin, F Nitrofurantoin, CN Gentamicin, IMP Imipenem, LEV Levofloxacin, LZD Linezolid, MIN Minocycline, MOX Moxifloxacin, MUP Mupirocin, NOR Norfloxacin, OX Oxacillin, P Penicillin, PRS Pristinamycin, RIF Rifampicin, SYN Quinupristin/Dalfopristin, TEI Teicoplanina, TET Tetraciclina (Tetracycline), TOB Tobramycin, SXT Sulfamethoxazole/Trimethoprim, VA Vancomycin.

MSSA meticillin-susceptible *Staphylococcus aureus*; MRSA meticillin-resistant *S. aureus*; MRSP meticillin-resistant *S. pseudintermedius*; MRSE meticillin-resistant *Staphylococcus epidermidis*; MRSS meticillin-resistant *Staphylococcus schleiferi*; ATCC American Type Culture Collection; FMV-UL Faculty of Veterinary Medicine, University of Lisbon.

Table S2 Minimal Inhibitory Concentrations of standard microbial agents for *Pseudomonas aeruginosa* and *P. fluorescens*

Strain Antimicrobial	P. aeruginosa ATCC®15442 ™	P. aeruginosa ATCC®27853 ™	P. aeruginosa FMV114/2014	P. aeruginosa FMV74/2015	P. aeruginosa FMV26/2016	P. aeruginosa FMV27/2016	P. aeruginosa FMV49/2016	P. aeruginosa FMV02/2017	P. aeruginosa FMV42/2017	P. fluorescens FMV85/2015	P. fluorescens FMV147/2015
A/S	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8
AK	≤8	≤8	≤8	≤8	≤8	≤8	16	≤8	≤8	≤8	≤8
AM	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16
AUG	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8	>16/8
AZT	4	4	4	4	4	4	4	4	4	4	4
C	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16
CAZ	≤1	≤1	≤1	≤1	2	≤1	≤1	≤1	≤1	≤1	16
CF	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16
CL	4	4	≤2	4	≤2	≤2	≤2	4	4	4	4
CP	≤0.5	≤0.5	≤0.5	>2	≤0.5	≤0.5	>2	≤0.5	>2	≤0.5	>2
CPE	≤1	2	2	8	8	8	8	4	8	4	8
CTX	16	16	16	8	16	16	16	>32	32	32	>32
CXM	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16
DOR	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1
ETP	>1	>1	>1	>1	>1	>1	>1	>1	>1	>1	>1
FD	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64
FOS	≤32	≤32	≤32	64	≤32	≤32	>64	≤32	64	≤32	64
FOX	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16
GM	≤2	≤2	≤2	4	8	8	8	4	4	4	≤2
IMP	≤1	≤1	≤1	2	≤1	≤1	≤1	≤1	≤1	≤1	4
LVX	≤2	≤1	≤1	>4	≤1	≤1	>4	≤1	>4	≤1	>4
MEM	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1
MIN	>8	>8	>8	>8	>8	>8	>8	>8	>8	>8	>8
NA	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16	>16
NXN	≤0.5	≤0.5	≤0.5	>1	1	≤0.5	>1	>1	>1	1	>1
P/T	≤8	≤8	≤8	≤8	≤8	≤8	≤8	16	≤8	≤8	16
PI	≤8	≤8	≤8	≤8	≤8	≤8	≤8	16	≤8	≤8	16
T/S	>4/76	>4/76	>4/76	>4/76	>4/76	>4/76	>4/76	>4/76	>4/76	>4/76	>4/76
TE	>8	>8	>8	>8	>8	>8	>8	>8	>8	>8	>8
TGC	>2	>2	>2	>2	>2	>2	>2	>2	>2	>2	>2
TO	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≤2

a - Susceptibility was assessed according to Clinical and Laboratory Standards Institute (CLSI) guidelines M100-S27.

**Abbreviations** A/S Ampicillin/Sulbactam, AK Amikacin, AM Ampicillin, AUG Amoxicillin/K Clavulanate, AZT Aztreonam, C Chloramphenicol, CAZ Ceftazidime, CF Cephalothin, CL Colistin, CP Ciprofloxacin, CPE Cefepime, CTX cefotaxime, DOR Doripenem, ETP Ertapenem, FD Nitrofurantoin, FOS Fosfomycin, FOX ceftiofur, GM Gentamicin, IMP Imipenem, LVX Levofloxacin, MEM meropenem, MIN Minocycline, NA Nalidixic Acid, NXN Norfloxacin, P/T Piperacillin/Tazobactam, PI Piperacillin, T/S Trimethoprim/Sulfamethoxazole, TE Tetracycline, TGC Tigecycline, TO Tobramycin.

ATCC American Type Culture Collection; FMV-UL Faculty of Veterinary Medicine, University of Lisbon.